Literature DB >> 28707414

Nucleophosmin 1 (NPM1) mutations in chronic myelomonocytic leukemia and their prognostic relevance.

Rangit Vallapureddy1, Terra L Lasho1, Katherine Hoversten1, Christy M Finke1, Rhett Ketterling2, Curtis Hanson2, Naseema Gangat1, Ayalew Tefferi1, Mrinal M Patnaik1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28707414      PMCID： PMC5730408          DOI： 10.1002/ajh.24861

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  12 in total

1.  DNMT3A mutations are associated with inferior overall and leukemia-free survival in chronic myelomonocytic leukemia.

Authors:  Mrinal M Patnaik; Daniela Barraco; Terra L Lasho; Christy M Finke; Curtis A Hanson; Rhett P Ketterling; Naseema Gangat; Ayalew Tefferi
Journal:  Am J Hematol       Date:  2016-12-07       Impact factor: 10.047

Review 2.  Chronic myelomonocytic leukemia: 2016 update on diagnosis, risk stratification, and management.

Authors:  Mrinal M Patnaik; Ayalew Tefferi
Journal:  Am J Hematol       Date:  2016-06       Impact factor: 10.047

3.  FLT3 and NPM1 mutations in myelodysplastic syndromes: Frequency and potential value for predicting progression to acute myeloid leukemia.

Authors:  Ashish Bains; Rajyalakshmi Luthra; L Jeffrey Medeiros; Zhuang Zuo
Journal:  Am J Clin Pathol       Date:  2011-01       Impact factor: 2.493

4.  Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations.

Authors:  Konstanze Döhner; Richard F Schlenk; Marianne Habdank; Claudia Scholl; Frank G Rücker; Andrea Corbacioglu; Lars Bullinger; Stefan Fröhling; Hartmut Döhner
Journal:  Blood       Date:  2005-07-28       Impact factor: 22.113

5.  Chronic myelomonocytic leukemia with nucleophosmin (NPM1) mutation.

Authors:  Jie Peng; Zhuang Zuo; Bin Fu; Yasuhiro Oki; Guilin Tang; Maitrayee Goswami; Priyanka Priyanka; Tariq Muzzafar; L Jeffrey Medeiros; Rajyalakshmi Luthra; Sa A Wang
Journal:  Eur J Haematol       Date:  2015-04-21       Impact factor: 2.997

Review 6.  Biological and clinical consequences of NPM1 mutations in AML.

Authors:  E M Heath; S M Chan; M D Minden; T Murphy; L I Shlush; A D Schimmer
Journal:  Leukemia       Date:  2017-01-23       Impact factor: 11.528

Review 7.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.

Authors:  Daniel A Arber; Attilio Orazi; Robert Hasserjian; Jürgen Thiele; Michael J Borowitz; Michelle M Le Beau; Clara D Bloomfield; Mario Cazzola; James W Vardiman
Journal:  Blood       Date:  2016-04-11       Impact factor: 22.113

8.  Molecular and prognostic correlates of cytogenetic abnormalities in chronic myelomonocytic leukemia: a Mayo Clinic-French Consortium Study.

Authors:  Emnet A Wassie; Raphael Itzykson; Terra L Lasho; Olivier Kosmider; Christy M Finke; Curtis A Hanson; Rhett P Ketterling; Eric Solary; Ayalew Tefferi; Mrinal M Patnaik
Journal:  Am J Hematol       Date:  2014-09-26       Impact factor: 10.047

9.  ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients.

Authors:  M M Patnaik; R Itzykson; T L Lasho; O Kosmider; C M Finke; C A Hanson; R A Knudson; R P Ketterling; A Tefferi; E Solary
Journal:  Leukemia       Date:  2014-04-03       Impact factor: 11.528

10.  Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemia.

Authors:  M M Patnaik; T L Lasho; P Vijayvargiya; C M Finke; C A Hanson; R P Ketterling; N Gangat; A Tefferi
Journal:  Blood Cancer J       Date:  2016-01-15       Impact factor: 11.037
View more
  8 in total

Review 1.  Genomics of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes.

Authors:  Mrinal M Patnaik; Terra L Lasho
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2020-12-04

Review 2.  Mutations in chronic myelomonocytic leukemia and their prognostic relevance.

Authors:  J Jian; Y Qiao; Y Li; Y Guo; H Ma; B Liu
Journal:  Clin Transl Oncol       Date:  2021-04-16       Impact factor: 3.405

Review 3.  Genetic Aspects of Myelodysplastic/Myeloproliferative Neoplasms.

Authors:  Laura Palomo; Pamela Acha; Francesc Solé
Journal:  Cancers (Basel)       Date:  2021-04-27       Impact factor: 6.639

4.  How I diagnose and treat chronic myelomonocytic leukemia.

Authors:  Mrinal M Patnaik
Journal:  Haematologica       Date:  2022-07-01       Impact factor: 11.047

5.  Diagnostic and therapeutic pitfalls in NPM1-mutated AML: notes from the field.

Authors:  Brunangelo Falini; Sofia Sciabolacci; Lorenza Falini; Lorenzo Brunetti; Maria Paola Martelli
Journal:  Leukemia       Date:  2021-04-20       Impact factor: 12.883

Review 6.  NPM1-Mutated Myeloid Neoplasms with <20% Blasts: A Really Distinct Clinico-Pathologic Entity?

Authors:  Fabio Forghieri; Vincenzo Nasillo; Ambra Paolini; Francesca Bettelli; Valeria Pioli; Davide Giusti; Andrea Gilioli; Corrado Colasante; Gloria Acquaviva; Giovanni Riva; Patrizia Barozzi; Rossana Maffei; Leonardo Potenza; Roberto Marasca; Claudio Fozza; Enrico Tagliafico; Tommaso Trenti; Patrizia Comoli; Giuseppe Longo; Mario Luppi
Journal:  Int J Mol Sci       Date:  2020-11-26       Impact factor: 5.923

Review 7.  Approaching First-Line Treatment in Patients With Advanced CMML: Hypomethylating Agents or Cytotoxic Treatment?

Authors:  Konstantinos Liapis; Ioannis Kotsianidis
Journal:  Front Oncol       Date:  2021-12-13       Impact factor: 6.244

Review 8.  The Role of Nucleophosmin 1 (NPM1) Mutation in the Diagnosis and Management of Myeloid Neoplasms.

Authors:  Katalin Kelemen
Journal:  Life (Basel)       Date:  2022-01-13
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.